{
  "trial_id": "NCT00830297",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "renal transplantation",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "eligibility for the standard immunosuppression of our center",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "tacrolimus, mycophenolate mofetil or mycophenolic acid, dexamethasone/prednisone",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "triple therapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "informed consent of the patient",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "patients with type 1 or type 2 diabetes",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "allergy against long-acting insulin",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has no underlying disease and is not on any medications. However, he has a severe gastrointestinal illness with laboratory evidence of hemolytic uremic syndrome (HUS), which may be related to Shiga-like toxin-producing E. coli (STEC) infection.",
  "_meta": {
    "topic_id": "32",
    "trial_id": "NCT00830297",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}